Search

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more

For mentors of applicants

As part of your support for the candidate applying for CBTH, the following is required from you:

Supervision and mentorship to be provided to the applicant during the CBTH award year.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Quality of Life and Symptoms

The goals of the SWG are:

To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.

Read more

Curriculum-Exam Committee call for interest

The aim of the Curriculum-Exam Committee is to promote harmonization in hematology training and education in Europe and beyond. It does this by offering tools and programs, such as the European Hematology Curriculum and the European Hematology Exam.

Read more

CRTH – reflections on a unique learning experience

CRTH (Clinical Research Training in Hematology) is a 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope.

Read more